Bayer and ERS Genomics announce licensing agreement for Genome Editing Patents
Bayer and ERS signed a patent license agreement whereby Bayer gains access to ERS’ CRISPR-Cas9 genome-editing patents for certain cross-divisional applications in Bayer’s core strategic…
Read More...
Read More...